HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer
Status:
Not yet recruiting
Trial end date:
2024-03-30
Target enrollment:
Participant gender:
Summary
This study is conducted in patients with advanced metastatic gastric cancer including
gastroesophageal junction cancer. This study includes two arms: A and B. Arm A (patients with
HER2 negative and PD-L1 CPS≥5 ) will receive HLX07 combination therapy with HLX10 and
chemotherapy (oxaliplatin+capecitabine) as first-line treatment. Arm B will receive HLX07
monotherapy as third-line or above treatment. All of eligible patients will receive study
drug treatment until loss of clinical benefit, unacceptable toxicity, death, withdrawal of
informed consent (whichever occurs first, HLX10 treatment up to 2 years).